|
|
|
|
UPDATE 3-Cephalon to buy generic firm Mepha for $590 mln
* Cephalon expands into generic drug business * Mepha acquisition to add to 2010 earnings * Cephalon shares rise 1.5 percent (Updates with analyst comment, CEO comment, share price ) BOSTON, Feb 1 (Reuters) - U.S.drugmaker Cephalon Inc <CEPH.O> said on...
|
|
|
Cephalon to buy generic firm Mepha for $590 million
BOSTON (Reuters) - U.S.drugmaker Cephalon Inc (CEPH.O) said on Monday it will buy Mepha AG, the Swiss generic drugmaker owned by Germany's Merckle family, for about $590 million (622.5 million Swiss francs) to diversify its product line and expand...
|
|
|
UPDATE 3-Cephalon to buy generic firm Mepha for $590 mln
* Mepha acquisition to add to 2010 earnings * Cephalon shares rise 1.5 percent (Updates with analyst comment, CEO comment, share price ) BOSTON, Feb 1 (Reuters) - U.S.drugmaker Cephalon Inc (CEPH.O: Quote, Profile, Research) said on Monday it will buy Mepha...
|
|
|
Research and Markets: Neuropathic Pain Report - Drug Pipeline Analysis and Market Forecasts to 2015
DUBLIN - (Business Wire) Research and Markets (http://www.researchandmarkets.com/research/88d5cf/neuropathic_pain) has announced the addition of GlobalData 's new report "" to their offering."" is an essential source of information and analysis on the global...
|
|
|
Research and Markets: Neuropathic Pain Report - Drug Pipeline Analysis and Market Forecasts to 2015
DUBLIN - (BUSINESS WIRE) - Research and Markets (http://www.researchandmarkets.com/research/88d5cf/neuropathic_pain) has announced the addition of GlobalData 's new report "" to their offering."" is an essential source of information and analysis on the...
|
